


Six Month Clinical Data

We are pleased announce the six month data for the EnligHTN I trial as presented during the American Heart Association meeting.

The EnligHTN I results at six months demonstrate that the EnligHTN renal denervation system delivers a **safe, rapid and sustained treatment effect** for hypertension as evidenced by few complications and a rapid immediate reduction in blood pressure that endured throughout the six month follow-up period. The EnligHTN system continues to be a promising therapy for the treatment of Resistant hypertension.


Key Findings (6 months)

Results: Office BP Reductions



- 76% of patients with ≥ 10 mmHg in SBP reduction
- 33.3% of patients < 140 mmHg in SBP
- Treatment delivered with:
 - No renal artery dissections, aneurysms, or stenoses
 - No flow-limiting renal artery vasospasms
 - No major vascular access complications
- The primary safety outcome was assessment of peri-procedural events
 - One patient with pre-existing proteinuria exhibited further increase over time
- There have been other minor procedural related events such as hematoma (5), vasovagal episodes (2), hypotensive episodes (2) and bradycardia (2)


Results: Ambulatory 24hr BP Reductions



EnligHTN therapy delivers a rapid and significant reduction in Ambulatory BP that is sustained through the 6M timeframe

“Managing blood pressure is a critical factor in maintaining the overall cardiovascular health of patients with drug-resistant hypertension,” said Dr. Vasilios Papademetriou, clinical associate-scientific collaborator from First Cardiology Clinic at Hippokraton Hospital in Athens, Greece, and a coordinating study investigator who presented the data at the AHA meeting.

“These results are important as they show that use of the EnligHTN multi-electrode renal denervation system can rapidly and safely decrease blood pressure, and the reduction is sustainable over time.”



2/3 of patients will have a great enough reduction in their BP to move to a lower stage of HTN classification / treatment and approximately 1/3 of patients treated with EnligHTN no longer meet HTN classification

If you have any questions and would like to discuss these results then please do not hesitate to call or e-mail.

More results will be released after the 12 month follow-up.